Loading…
Employees: 121
Size Shaanxi Micot Pharmaceutical Technology (2335.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $715M, the 663rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.00 on 18 Nov 2026.
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — |
| Gross profit | -HK$6.97M | -HK$7.13M | -HK$9.09M | -HK$9.55M |
| EBITDA | -HK$291M | -HK$159M | -HK$127M | -HK$106M |
| Net income | -HK$409M | -HK$198M | -HK$168M | -HK$207M |
| Free cash flow | HK$12.7M | -HK$167M | -HK$108M | -HK$111M |
| Capital expenditure | HK$19.1M | HK$18.4M | HK$1.41M | HK$2.27M |
| Total debt | n/a | HK$1.35B | HK$49.5M | HK$850M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2335.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.3% | -7.1% | 4th highest of 21 |
| Distance from 52-week high | -57.8% | -45.9% | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |